Figure 4.
MYXV reduces the tumor burden in vivo. (a) NOD/SCID mice engrafted with intraperitoneal Hs766T-FFluc tumors were treated with four doses of 108 ffu of vMyx-tdTr intraperitoneally starting at 6 days post engraftment (dpe) of cells or left untreated. Tumor burden was monitored at the indicated time points using bioluminescence imaging and D-luciferin as substrate. (b) Radiances from the peritoneal area of mice in a were calculated. *P < 0.05 between untreated and MYXV-treated groups. Error bars shown represent the mean plus/minus one standard standard deviation (Mean ± SD). ffu, foci forming units; FFluc, firefly luciferase; MYXV, Myxoma virus.